We further demonstrate that inhibiting AKT1 phosphorylation with MK-2206 not only reduced ENTPD5 levels but also prevented RhoA-induced SPARC production in glioblastoma cells with high p-AKT1 levels [Fig. 4c; Suppl. The gene discussed is ENTPD5; the disease is glioblastoma.